Clinical trials: Rectal Cancer, Radiotherapy
Rectal Cancer
TNFerade™ Plus Chemo/Radiation/Surgery for Rectal Cancer
The purpose of this study is to determine if the addition of TNFerade™ to pre-operative chemoradiotherapy increases the number of pathologic complete responses when compared to pre-operative chemoradiotherapy alone as assessed…
- Trial name
- NCT00137878
- Testing
- TNFerade™
- Where
- United States
- Sponsor
- GenVec
Rectal Cancer
Tecemotide (L-BLP25) in Rectal Cancer
The objective of this mechanistic study is to determine the impact of tecemotide (L-BLP25) administration on the mucinous glycoprotein 1 - (MUC1) specific immune response in subjects with newly diagnosed rectal cancer who are…
- Trial name
- SPRINT (NCT01507103)
- Testing
- Tecemotide (L-BLP25), cyclophosphamide (CPA), Chemoradiotherapy
- Where
- Netherlands
- Volunteers
- 124 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Prostate Cancer Patients Treated by Radiotherapy
Post-marketing Surveillance Regarding Efficacy and Safety of SpaceOAR™
A treatment with SpaceOAR™ hydrogel does reduce late toxicity Grad 2 and Grad 3 of radiation therapy in prostate cancer patients
- Trial name
- NCT01999660
- Testing
- SpaceOAR™ implantation
- Where
- Germany
- Volunteers
- 119 people
- Sponsor
- CS Diagnostics GmbH
Metastatic Colorectal Cancer
A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer
The purpose of this study is to investigate the safety and effects of IMM 101 in combination with a single targeted dose of radiation in patients with metastatic colorectal cancer in whom chemotherapy or other treatment has not…
- Trial name
- NCT01539824
- Testing
- Mycobacterium obuense, SBRT
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Immodulon Therapeutics Ltd
Colorectal Cancer
A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer
This single arm study will assess the efficacy and safety of treatment with Xeloda plus standard pelvic radiotherapy in participants with locally advanced rectal cancer.
- Trial name
- NCT00796718
- Testing
- Standard radiotherapy, Capecitabine [Xeloda]
- Where
- 2 sites in Slovakia
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Rectal Cancer
A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer
The purpose of this study is to determine the pathological complete tumor response rate.
- Trial name
- NCT02694718
- Testing
- Capecitabine, Oxaliplatin
- Where
- 6 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
An Observational Study of Xeloda (Capecitabine) and Oxaliplatin Prior and Concurrent To Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer
This observational study is a follow-up study of protocol ML18280. Survival data of patients who took part in and concluded study ML18280 will be collected for up to 5 years after LPLV of ML18270.
- Trial name
- NCT01339832
- Where
- 5 sites in Switzerland
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Rectal Cancer
A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
An open-label, Phase 1b, dose escalation study evaluating the safety and tolerability of the PARP inhibitor Veliparib in combination with capecitabine and radiation in subjects with locally advanced rectal cancer (LARC).
- Trial name
- NCT01589419
- Testing
- veliparib, capecitabine, radiation
- Where
- 6 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rectal Cancer
A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer
This phase Ib/II study is a prospective, open-label, single arm, nonrandomized study of PEP503(radio-enhancer). There are 2 portions in this study.
- Trial name
- NCT02465593
- Testing
- PEP503, 5-fluorouracil, capecitabine
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- PharmaEngine
Rectal Neoplasms
Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer
The purpose of this phase II trial is to determine the efficacy and safety of the combination of oxaliplatin, capecitabine and radiotherapy as preoperative therapy in locally advanced cancers of the rectum.
- Trial name
- PROCTFUL (NCT00263029)
- Testing
- Oxaliplatin, Capecitabine, Radiotherapy
- Volunteers
- 18 people
- Sponsor
- Sanofi
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
111Indium-labelled IPN01087 (111In-IPN01087) is developed as a radioactive diagnostic imaging agent in patients with colorectal or pancreatic cancer.
- Trial name
- NCT04632199
- Testing
- 111In-IPN01087 Low dose, 111In-IPN01087 High dose
- Where
- 5 sites in Belgium, France
- Sponsor
- Ipsen
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Colorectal Cancer, Rectal Bleeding
Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding
The objective of this study is to find the maximum tolerated dose and preliminary efficacy of desmopressin as an haemostatic agent, when is administered to patients with colorectal cancer and rectal bleeding, before specific…
- Trial name
- NCT01623206
- Testing
- Desmopressin
- Where
- 2 sites in Argentina
- Volunteers
- 30 people
- Sponsor
- Laboratorio Elea Phoenix S.A.